Pentoxifylline in COVID-19 and considerations for its research in long COVID
Open Access
- 24 October 2024
- journal article
- review article
- Published by Springer Nature in Inflammation Research
- Vol. 73 (12) , 2057-2068
Abstract
Introduction: Pentoxifylline (PTX) affects most blood components and the blood vessels, potentially modulating various conditions. Due to its impact on markers linked to COVID-19 severity, research has explored PTX for acute COVID-19. Following the widespread administration of COVID-19 vaccinations, there has been a notable and consistently growing increase in research focusing on long COVID. Consequently, our examination of relevant acute COVID-19 data shall additionally be contextualized into long COVID research. Methods: Various Databases were searched until July 2024 for all primary clinical studies on Pentoxifylline (PTX) in COVID-19. Results: Studies were on acute infection with SARS-CoV-2 where PTX was an adjuvant to standard therapy for ethical and practical reasons under the circumstance. PTX generally reduced hospitalization duration and improved some inflammatory markers, but its impact on mortality was inconsistent. Adverse events were minimal. Meta-analysis revealed a significant reduction in hospitalization duration. Conclusion: This systematic review and meta-analysis suggest that adding pentoxifylline (PTX) to standard COVID-19 therapy may significantly reduce hospitalization duration and improve some inflammatory markers. However, its impact on mortality rates is inconclusive. Adverse events are minimal. PTX can be favorable as an add-on in managing acute COVID-19 and could reduce the risk of long COVID, as well as assist in managing many of its most common symptoms.Keywords
Funding Information
- Cairo University
This publication has 60 references indexed in Scilit:
- Prevalence and risk factors for persistent symptoms after COVID-19: a systematic review and meta-analysisClinical Microbiology and Infection, 2023
- Long COVID and possible preventive optionsInflammopharmacology, 2023
- Association of serum ferritin with severity and clinical outcome in COVID-19 patients: An observational study in a tertiary healthcare facilityClinical Epidemiology and Global Health, 2023
- Pilot study: management with pentoxifylline in patients with chronic liver disease and COVID-19Annals of Hepatology, 2022
- Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysisEuropean Journal of Internal Medicine, 2021
- Aortic Thrombosis in the Course of Covid-19 Disease; Two Rare CasesAnnals of Vascular Surgery, 2021
- Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19The American Journal of Emergency Medicine, 2021
- Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19Computational and Structural Biotechnology Journal, 2021
- COVID-19 Infection and Haematological Involvement: a Review of Epidemiology, Pathophysiology and Prognosis of Full Blood Count FindingsSN Comprehensive Clinical Medicine, 2020
- Pentoxifylline: A New Drug for the Treatment of Intermittent Claudication; Mechanism of Action, Pharmacokinetics, Clinical Efficacy and Adverse EffectsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1984